The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | FLAMSU-Bu conditioning doesn’t improve outcome in AML/MDS irrespective of pre-transplant MRD status
Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, University of Birmingham, Birmingham, UK, discusses the results of the UK NCRI FIGARO trial. This prospective, randomized trial compared the FLAMSA-Bu regimen (cytosine arabinoside/amsacrine cytoreduction, followed by a fludarabine/busulfan) with a standard reduced-intensity conditioning regimen in patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) undergoing allogeneic stem cell transplantation. This trial also represents the first prospective evaluation of the impact of pre-transplant MRD levels on transplant outcome. Data showed that the FLAMSA-Bu regimen was not associated with improved transplant outcome in patients who were MRD positive pre-transplant. Prof. Craddock goes on to discuss the COSI and AMADEUS trials, also part of the IMPACT trials network. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
